Spinal Muscular Atrophy - The disease and its treatments
Main Article Content
Downloads
Article Details
Copyright (c) 2021 Chen KY.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Spinal Muscular Atrophy: MedlinePlus Genetics. MedlinePlus, U.S. National Library of Medicine. Link: https://bit.ly/3hHkHjd
Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, et al. (1999) Single Nucleotide Difference That Alters Splicing Patterns Distinguishes the SMA Gene SMN1 From the Copy Gene SMN2. Hum Mol Genet 8: 1177-1183. Link: https://bit.ly/3xMrBJB
About Spinal Muscular Atrophy (SMA). Cure SMA. Link: https://bit.ly/3escdux
Waldrop MA, Elsheikh BH (2020) Spinal Muscular Atrophy in the Treatment Era. Neurol Clin 38: 505–518. Link: https://bit.ly/36GGkKg
Diseases - SMA - Types Of Overview. Muscular Dystrophy Association. Link: https://bit.ly/3xXcRHS
Spinal Muscular Atrophy Fact Sheet. National Institute of Neurological Disorders and Stroke, U.S. Department of Health and Human Services. Link: https://bit.ly/3inqw4O
Treatment for Spinal Muscular Atrophy (SMA). Cure SMA. Link: https://bit.ly/36Jx2xf
Antisense Technology. Ionis Pharmaceuticals, Inc. Link: https://bit.ly/3wM0oFA
Our Medicines. Ionis Pharmaceuticals, Inc. Link: https://bit.ly/3rgluLl
Product Portfolio.
The Discovery of Spinraza. Cure SMA 2018.
Hua Y, Vickers TA, Okunola HL, Bennett CF, Krainer AR (2008) Antisense Masking of an HnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice. Am J Hum Genet 82: 834-848. Link: https://bit.ly/36FJQEJ
Spinraza. Cure SMA. Link: https://bit.ly/3kmvIs8
Biogen Idec and Isis Pharmaceuticals Announce Global Collaboration for Antisense Program Targeting Spinal Muscular Atrophy. Biogen. Link: https://bit.ly/2USwTVD
Early-Onset SMA (Type 1): SPINRAZA® (Nusinersen). Official Patient Site. Link: https://bit.ly/3kqLpia
Commissioner (2016) Office of the. FDA Approves First Drug for Spinal Muscular Atrophy. U.S. Food and Drug Administration, FDA. Link: https://bit.ly/3wImLMf
Anonymous. Spinraza. European Medicines Agency. Link: https://bit.ly/36CRxvz
Zolgensma. Cure SMA. Link: https://bit.ly/3wJTvoq
Evrysdi. Cure SMA. Link: https://bit.ly/3z4NaFM
Marta F (2020) Spinraza-Zolgensma Combination Well-Tolerated in Children with SMA. Link: https://bit.ly/2TdAwEW